Patients treated with on dupilumab showed significant improvement in sustained BP remission compared with those on placebo.
Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoidIf approved, Dupixent would be the first and only ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback